Siemens Healthineers Adr

Good morning ladies and gentlemen and welcome to Siemens Healthineers conference call. As a reminder, this conference is being recorded. Before we begin, I would like to draw your attention to the Safe Harbor Statement on page 2 of the Siemens Healthineers presentation. This conference call may include forward-looking statements. These statements are based on the company's current expectations and certain assumptions, and are therefore subject to certain risks and uncertainties. At this time, I would like to turn the call over to your host today, Mr. Mark Kubanek, Head of Investor Relations. Please go ahead, sir.

Thank you, operator. Good morning and welcome to our first quarter earnings call. I'd like to thank each of you for joining us today. At 7 a.m. this morning, we published our Q1 2025 results. All the related material for today's results release is available on the IR section of the Siemens Healthineers webpage. In a moment, we'll hear directly from our CEO, Bernd Montag, and our CFO, Jochen Schmitz. and their presentation. After it, we will have a Q&A session. To ensure everyone gets the opportunity to engage, we kindly ask that each participant limit themselves to a maximum of two questions. Additionally, please note that a full transcript and recording of today's call will be made and also made available on our investor relations webpage shortly after the session ends. Again, thank you for being here. And now I'll turn it over to Bernd Montag.

Thank you, Mark. Dear analysts and investors, welcome to our Q1 earnings call. Great that you can join us. We have made a successful start into the new fiscal year. In Q1, we grew by nearly 6%, well within our full-year guidance range. Adjusted earnings per share also grew, driven by top-line growth and margin expansion. In addition, we had a very good order intake quarter again. We achieved an excellent equipment book-to-bill of 1.21, which was driven by equipment book-to-bills above 1 across all businesses and markets. This broad-based order intake was driven by value partnerships and large deals as well as transactional business. Our imaging segment started strongly in the new fiscal year. With 8% revenue growth, the imaging margin was held back by special items in Q1, but was strong on an underlying basis. Jochen will later provide some additional color on these more temporary effects. Advanced therapy started in similar rain, with good growth and some quarterly volatility in the margin. At Varian, we are proud of how the combination of Varian and Siemens Healthineers continues to bear fruit, with very good growth and the margin continuing to expand to above 17% in Q1. And we are also proud that the transformation of the diagnostic segment continues to progress, achieving a margin of 8% in Q1. And last but certainly not least, our cash performance was extremely strong with free cash flow more than tripling compared to Q1 last year. Hence, with this quarter in the books, we confirm our outlook for fiscal year 2025. And I hand it over to Jochen.